Valproic Acid, Sodium Salt is a branched chain fatty acid which is reported to inhance central GABAergic neurotransmission and inhibit Sodium Channel Protein (Na+ channels). This compound is also reported to cause inositol depletion, activate the ERK pathway, inhibit GSK-3α and GSK-3β. Valproic Acid has been reported to be a potent inhibitor of HDAC (histone deacetylase) in vitro (IC50 = 400 μM for HDAC1), thereby relieving HDAC-dependent transcriptional repression and causes the hyperacetylation of histones in cultured cells. In animal studies, Valproic Acid has been observed to reduce tumor growth and metastasis formation. Additionally, Valproic Acid is reported to activate Wnt-dependent gene expression and to mimic trichostatin A (sc-3511) in the inhibition of histone deacetylase. This compound is also an inhibitor of the CYP2C9 enzyme.
Metabolites of Valproic Acid are also available as:
Valproic Acid (sc-213144)
3-Hydroxy Valproic Acid (sc-209599)
3-Keto Valproic Acid Sodium Salt (sc-216476)
4-Hydroxy Valproic Acid Sodium Salt (Mixture of Diastereomers) (sc-216870)
rac 5-Hydroxy Valproic Acid Sodium Salt (sc-208266)
Valproic Acid β-D-Glucuronide Allyl Ester (sc-220360)
Valproic Acid β-D-Glucuronide (sc-213145)
Labelled forms of Valproic Acid are available as:
Valproic Acid-d6 (sc-213146)
Valproic Acid-d6 β-D-Glucuronide (sc-220361)
rac 5-Hydroxy Valproic Acid-d7 Sodium Salt (sc-219789)
1. Della Paschoa, O E., et al., 1998. Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. British journal of pharmacology. 125(7): 1610-6. PMID: 9884091
2. Tunnicliff, G., et al., 1999. Actions of sodium valproate on the central nervous system. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 50(3): 347-65. PMID: 10574466
3. Phiel, C J., et al., 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. The Journal of biological chemistry. 276(39): 36734-41. PMID: 11473107
4. Göttlicher, M., et al., 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The EMBO journal. 20(24): 6969-78. PMID: 11742974
5. Gökçe, Selim., et al., 2010. Valproic acid-associated vanishing bile duct syndrome. Journal of child neurology. 25(7): 909-11. PMID: 20388938
See how others have used Valproic acid sodium salt. Click on the entry to view the PubMed entry .
PMID: # 28153532 Segura-Ulate, I. et al. 2017. Neuropharmacology. 117: 149-157.
PMID: # 27343825 2016. Mol. Cell. Neurosci. 75: 27-35.
PMID: # 20381581 Liu, B. et al. 2010. Exp. Hematol. 38: 685-695.
PMID: # 14871994 Takai, N. et al. 2004. Clin. Cancer Res. 10: 1141-1149.
PMID: # 402258 Pinder, RM. et al. 1977. Drugs. 13: 81-123.
PMID: # 10812195 Johannessen, CU. et al. 2000 Aug-Sep. Neurochem. Int. 37: 103-110.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.